We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




Molecular Blood Test Kit Detects Gastric Cancer Early

By LabMedica International staff writers
Posted on 09 Nov 2020
Gastric cancer (GC) is the fifth most common cancer and the third-leading cause of cancer deaths worldwide. More...
GC mortality is high due to late presentation. In most countries, mass screening is neither feasible nor cost-effective because such screening methods are costly and invasive, with poor compliance.

MicroRNAs (miRNAs or miRs) are small non-coding RNAs that regulate gene expression post-transcriptionally. Aberrant expression of miRNAs has been implicated in the pathogenesis of many diseases, including cancer. Cell-free miRNAs have been shown to circulate stably in serum and plasma, and dysregulation of their expressions correlate with cancer onset and progression, making them attractive biomarker candidates.

Gastroenterologists and their colleagues associated with the National University of Singapore (Singapore) conducted a three-phase, multicenter study comprising 5,248 subjects from Singapore and Korea. The case–control cohort included 472 Singaporean Chinese subjects, including 236 cancer and 236 matched control subjects.

A clinical assay was developed and validated in a prospective cohort of 4,566 symptomatic subjects who underwent endoscopy. Assay performance was confirmed with histological diagnosis and compared with Helicobacter pylori (HP) serology, serum pepsinogens (PGs), ‘ABC’ method, carcinoembryonic antigen (CEA) and cancer antigen 19–9 (CA19-9). The absolute expression (copy numbers) of 578 candidate miRNAs were quantified in each patient and control biospecimen using miRNA-specific RT-qPCR assays (MiRXES, JTC MedTech Hub, Singapore) via a highly controlled workflow. Total RNA from 200 µL of patient and control serum specimen was isolated using miRNeasy serum/plasma miRNA isolation kit (Qiagen, Hilden, Germany).

The team developed a clinical assay for detection of gastric cancer based on a 12-miRNA biomarker panel. The 12-miRNA panel had area under the curve (AUC) = 0.93 and AUC = 0.92 in the discovery and verification cohorts, respectively. In the prospective study, overall sensitivity was 87.0% at specificity of 68.4%. AUC was 0.848, higher than HP serology (0.635), PG 1/2 ratio (0.641), PG index (0.576), ABC method (0.647), CEA (0.576) and CA19-9 (0.595). The number needed to screen is 489 annually. It is cost-effective for mass screening relative to current practice.

The authors concluded that they had developed and validated a serum miRNA biomarker panel assay as a risk assessment tool for detecting GC. This assay is a useful adjunct in the armamentarium for cancer screening and has the potential to be a cost-effective mass screening tool for GC. The study was first published on October 7, 2020 in the BMJ journal Gut.





New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.